Key Zealand peptide competences
Zealand is a Danish biopharmaceutical company dedicated to the discovery and development of innovative peptide drugs. The Company target diseases where it believes existing treatments fail to adequately serve the medical needs of patients and the market potential for improved treatments through the use of peptide drugs is high. The Company focuses on three therapeutic areas: metabolic (diabetes and obesity), gastrointestinal and cardiovascular diseases.
Since 1998, Zealand’s scientists have built a strong and growing pipeline of novel peptide drug candidates, many of which are now in clinical development. Currently, Zealand and its partners have one marketed product, drug candidates in Phase III clinical development and five drug candidates in Phase I and Phase II clinical development. Zealand also has one drug candidate in preclinical development that has been approved to enter clinical development.
As part of the Company’s operations, Zealand has formed clinical development partnerships with leading pharmaceutical companies Sanofi, Eli Lilly, Boehringer Ingelheim, Wyeth (now Pfizer), Helsinn Healthcare and AbbVie.
Zealand’s specialized know-how in peptide chemistry enables the generation of novel peptide molecules with unique therapeutic qualities.